Unnati Pharmax

Testo-C Testosterone Cypionate Injection 10mL
Composition: Testosterone Cypionate 200mg/mL Injection
International Trade Name: Depo-Testosterone®

Testo-C is a high-quality Testosterone Cypionate injection, a long-acting ester of testosterone widely recognized under the international brand name Depo-Testosterone®. Manufactured in WHO-GMP certified facilities, Testo-C Injection is supplied by trusted pharmaceutical exporters from India to support advanced global hormone replacement and andrology treatment programs.

Testosterone Cypionate is an androgenic anabolic steroid that helps restore and maintain normal testosterone levels in males with hypogonadism or other testosterone deficiency conditions. It promotes the development and maintenance of male secondary sexual characteristics, supports muscle mass, bone density, libido, and overall physical well-being. Testo-C Injection is primarily indicated for testosterone replacement therapy (TRT) in males with primary or secondary hypogonadism.

Testo-C Testosterone Cypionate Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The injection is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, endocrinology clinics, fertility centers, and international pharmaceutical distributors.

V-Strant Fulvestrant Injection 5mL 50mg
Composition: Fulvestrant 50mg / 5mL Solution for Injection
International Trade Name: Faslodex®

V-Strant is a high-quality Fulvestrant injectable formulation, a selective estrogen receptor degrader (SERD) widely recognized under the international brand name Faslodex®. Manufactured in WHO-GMP certified facilities, V-Strant Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hormone receptor-positive metastatic breast cancer.

Fulvestrant works by binding to estrogen receptors, blocking estrogen signaling, and promoting receptor degradation, thereby inhibiting the growth of estrogen-dependent breast cancer cells. V-Strant Injection is primarily indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, especially in patients with disease progression following prior endocrine therapy.

V-Strant Fulvestrant Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Fulvenat Fulvestrant Injection
Composition: Fulvestrant 250mg / 5mL Solution for Injection
International Trade Name: Faslodex®

Fulvenat is a high-quality Fulvestrant injectable formulation, a selective estrogen receptor degrader (SERD) widely recognized under the international brand name Faslodex®. Manufactured in WHO-GMP certified facilities, Fulvenat Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hormone receptor-positive metastatic breast cancer.

Fulvestrant works by binding to estrogen receptors, blocking estrogen signaling and promoting receptor degradation, thereby inhibiting the growth of estrogen-dependent breast cancer cells. Fulvenat Injection is primarily indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, especially in cases resistant to previous endocrine therapy.

Fulvenat Fulvestrant Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Fulvenat 250 mg Injection
Composition: Fulvestrant 250 mg per vial
International Trade Name: Faslodex®

Fulvenat 250 mg Injection is a high-quality Fulvestrant formulation, a biosimilar equivalent of the internationally recognized selective estrogen receptor degrader (SERD) Faslodex®. Manufactured in WHO-GMP certified facilities, Fulvenat is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hormone receptor-positive breast cancer.

Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to estrogen receptors, blocking estrogen signaling and promoting receptor degradation. This action inhibits the growth of estrogen receptor-positive (ER+) breast cancer cells and helps overcome resistance to other endocrine therapies.

Fulvenat 250 mg Injection is primarily indicated for the treatment of postmenopausal women with estrogen receptor-positive advanced or metastatic breast cancer, especially in patients who have experienced disease progression following anti-estrogen therapy.

Fulvenat 250 mg Injection is manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

Ribashiv-200 Tablets
Composition: Ribavirin 200 mg per tablet
International Trade Name: Copegus®

Ribashiv-200 is a high-quality Ribavirin tablet, a biosimilar equivalent of the internationally recognized antiviral product Copegus®. Manufactured in WHO-GMP certified facilities, Ribashiv-200 is supplied by trusted pharmaceutical exporters from India to support global antiviral and hepatology treatment programs.

Ribavirin is a broad-spectrum antiviral agent that interferes with viral RNA synthesis and replication. It is commonly used in combination with other antiviral medications for the treatment of chronic hepatitis C and certain viral hemorrhagic fevers, helping to reduce viral load and improve sustained virologic response rates.

Ribashiv-200 Tablets are primarily indicated for the treatment of chronic hepatitis C infection as part of combination antiviral therapy, and for selected viral infections as prescribed by a healthcare professional.

Ribashiv-200 Tablets are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, hepatology clinics, government health programs, and international pharmaceutical distributors.

THALIDOMYRA 100 mg Capsules
Composition: Thalidomide IP 100 mg per capsule
International Trade Name: Contergan® / Distaval®

THALIDOMYRA 100 mg is a high-quality Thalidomide capsule, a biosimilar equivalent of the internationally recognized immunomodulatory and anti-angiogenic agents Contergan® and Distaval®. Manufactured in WHO-GMP certified facilities, THALIDOMYRA is supplied by trusted pharmaceutical exporters from India to support advanced global oncology and immunology treatment programs.

Thalidomide is an immunomodulatory agent with anti-inflammatory, anti-angiogenic, and antineoplastic properties. It works by modulating cytokine production, inhibiting tumor necrosis factor-alpha (TNF-α), and suppressing abnormal blood vessel formation, thereby helping to control tumor growth and immune-mediated disorders.

THALIDOMYRA 100 mg Capsules are primarily indicated for the treatment of multiple myeloma (as part of combination therapy), erythema nodosum leprosum (ENL), and other selected immunological and oncological conditions as prescribed by a healthcare professional.

THALIDOMYRA 100 mg Capsules are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, specialty hospitals, government health programs, and international pharmaceutical distributors.

Lapalieva 250 mg Tablets
Composition: Lapatinib 250 mg per tablet
International Trade Name: Tykerb®

Lapalieva 250 mg is a high-quality Lapatinib tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy Tykerb®. Manufactured in WHO-GMP certified facilities, Lapalieva is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in HER2-positive cancers.

Lapatinib is a dual tyrosine kinase inhibitor that blocks the intracellular domains of both HER2 (ErbB2) and EGFR (ErbB1) receptors. By inhibiting these pathways, Lapalieva helps prevent tumor cell growth, proliferation, and survival, making it an effective targeted therapy for HER2-overexpressing malignancies.

Lapalieva 250 mg Tablets are primarily indicated for the treatment of HER2-positive metastatic breast cancer, especially in patients who have previously received trastuzumab, anthracycline, and taxane-based therapy, often in combination with other anticancer agents.

Lapalieva 250 mg Tablets are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

Relugonat Relugolix Tablets 120mg
Composition: Relugolix 120mg Tablets
International Trade Name: Orgovyx®

Relugonat 120mg is a high-quality Relugolix tablet formulation, a gonadotropin-releasing hormone (GnRH) receptor antagonist widely recognized under the international brand name Orgovyx®. Manufactured in WHO-GMP certified facilities, Relugonat is supplied by trusted pharmaceutical exporters from India to support advanced global urology and oncology treatment programs, particularly in hormone-sensitive prostate cancer.

Relugolix works by directly inhibiting GnRH receptors in the pituitary gland, leading to rapid suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby reducing testosterone production without the initial testosterone surge seen with GnRH agonists. Relugonat 120mg Tablets are primarily indicated for the treatment of advanced prostate cancer and other hormone-dependent conditions where medical castration is required.

Relugonat Relugolix Tablets 120mg are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, urology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Bd Octerio 30 mg Injection
Composition: Octreotide 30 mg per vial
International Trade Name: Sandostatin®

Bd Octerio 30 mg is a high-quality Octreotide injection, a biosimilar equivalent of the internationally recognized somatostatin analog Sandostatin®. Manufactured in WHO-GMP certified facilities, Bd Octerio is supplied by trusted pharmaceutical exporters from India to support advanced global endocrinology and oncology treatment programs.

Octreotide is a synthetic octapeptide that mimics natural somatostatin, inhibiting the release of several hormones, including growth hormone, insulin, and glucagon. By modulating hormone secretion, Bd Octerio is effective in managing acromegaly, neuroendocrine tumors, and related hormone-secreting disorders.

Bd Octerio 30 mg Injection is primarily indicated for the treatment of acromegaly, symptoms associated with neuroendocrine tumors (such as carcinoid syndrome), and vasoactive intestinal peptide-secreting tumors (VIPomas), as prescribed by a healthcare professional.

Bd Octerio 30 mg Injection is manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, export-grade vials with complete regulatory documentation, making it suitable for hospitals, endocrinology clinics, specialty centers, government health programs, and international pharmaceutical distributors.

Fempro Letrozole 2.5mg Tablets
Composition: Letrozole 2.5mg Tablets
International Trade Name: Femara®

Fempro 2.5mg is a high-quality Letrozole tablet formulation, a potent non-steroidal aromatase inhibitor widely recognized under the international brand name Femara®. Manufactured in WHO-GMP certified facilities, Fempro is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hormone receptor-positive breast cancer.

Letrozole works by selectively inhibiting the aromatase enzyme, which is responsible for the peripheral conversion of androgens to estrogens, thereby reducing estrogen levels and limiting the growth of estrogen-dependent breast cancer cells. Fempro 2.5mg Tablets are primarily indicated for the treatment of hormone receptor-positive early or advanced breast cancer in postmenopausal women, as well as for adjuvant therapy following surgery.

Fempro Letrozole 2.5mg Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Bendit Bendamustine Injection IP 100 mg
Composition: Bendamustine Hydrochloride 100 mg per vial
International Trade Name: Treanda®

Bendit 100 mg Injection is a high-quality chemotherapeutic agent, a biosimilar equivalent of the internationally recognized anticancer drug Treanda®. Manufactured in WHO-GMP certified facilities, Bendit is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Bendamustine is an alkylating agent with unique cytotoxic and antimetabolite properties. It works by forming cross-links in DNA strands, leading to disruption of DNA replication and transcription, and ultimately causing apoptosis in rapidly dividing cancer cells. Bendit is effective against various hematologic malignancies and selected solid tumors.

Bendit Bendamustine Injection 100 mg is primarily indicated for the treatment of chronic lymphocytic leukemia (CLL), indolent B-cell non-Hodgkin lymphoma, and other hematologic cancers as determined by an oncologist.

Bendit 100 mg Injection is manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, export-grade vials with complete regulatory documentation, making it suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

Udikast SR 450 mg Tablets
Composition: Ursodeoxycholic Acid 450 mg (Sustained Release)
International Trade Name: Actigall®

Udikast SR 450 mg is a high-quality sustained-release formulation of Ursodeoxycholic Acid (UDCA), a biosimilar equivalent of the internationally recognized product Actigall®. Manufactured in WHO-GMP certified facilities, Udikast SR is supplied by trusted pharmaceutical exporters from India to support global hepatology and gastroenterology treatment programs.

Ursodeoxycholic Acid is a naturally occurring hydrophilic bile acid that improves bile flow, reduces cholesterol saturation in bile, and protects hepatocytes from toxic bile acids. The sustained-release formulation of Udikast SR ensures prolonged therapeutic action, better patient compliance, and consistent bile acid levels throughout the day.

Udikast SR 450 mg Tablets are primarily indicated for the management of cholesterol gallstones, primary biliary cholangitis (PBC), and various cholestatic liver disorders. It also supports improved liver function in patients with chronic liver diseases.

Udikast SR 450 mg Tablets are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, gastroenterology clinics, government health programs, and international pharmaceutical distributors.

Leucokast 50 Leucovorin Calcium Injection 50mg
Composition: Leucovorin Calcium 50mg / mL Injection
International Trade Name: Wellcovorin®

Leucokast 50 is a high-quality Leucovorin Calcium 50mg Injection, a reduced form of folic acid widely recognized under the international brand name Wellcovorin®. Manufactured in WHO-GMP certified facilities, Leucokast 50 Injection is supplied by trusted pharmaceutical exporters from India to support advanced global chemotherapy and folate supplementation programs.

Leucovorin Calcium acts as a folate supplement and a chemoprotective agent. It is primarily used to reduce the toxic effects of methotrexate therapy, enhance the efficacy of fluorouracil in cancer treatment, and treat folate deficiency. Leucokast 50mg Injection is indicated for use in oncology patients receiving high-dose methotrexate therapy, in combination with fluoropyrimidine chemotherapy, and for the treatment of megaloblastic anemia due to folate deficiency.

Leucokast 50 Leucovorin Calcium Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, hospitals, and international pharmaceutical distributors.

Xarelto Rivaroxaban 15mg Tablets
Composition: Rivaroxaban 15mg Tablets
International Trade Name: Xarelto®

Xarelto 15mg is a high-quality Rivaroxaban formulation, a direct oral anticoagulant (DOAC) widely recognized under the international brand name Xarelto®. Manufactured in WHO-GMP certified facilities, this product is supplied by trusted pharmaceutical exporters from India to support advanced global cardiovascular and thromboembolic treatment programs.

Rivaroxaban is a selective and direct Factor Xa inhibitor that prevents thrombin generation and clot formation without the need for routine coagulation monitoring. Xarelto 15mg is primarily indicated for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and prevention of recurrent thromboembolic events.

Xarelto Rivaroxaban 15mg Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, cardiology clinics, and international pharmaceutical distributors.

Mitolem Mitomycin Injection 10mg
Composition: Mitomycin 10mg / Vial Injection
International Trade Name: Mutamycin®

Mitolem 10mg is a high-quality Mitomycin injectable formulation, a potent alkylating antineoplastic agent widely recognized under the international brand name Mutamycin®. Manufactured in WHO-GMP certified facilities, Mitolem Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Mitomycin works by cross-linking DNA strands, thereby inhibiting DNA synthesis and inducing apoptosis in rapidly dividing cancer cells. Mitolem 10mg Injection is primarily indicated for the treatment of various malignancies, including gastrointestinal, breast, pancreatic, and bladder cancers, either as monotherapy or in combination with other chemotherapeutic agents.

Mitolem Mitomycin Injection 10mg is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Tamoxican 20 mg Tablets
Composition: Tamoxifen Citrate 20 mg per tablet
International Trade Name: Soltamox®

Tamoxican 20 mg is a high-quality Tamoxifen Citrate tablet, a biosimilar equivalent of the internationally recognized selective estrogen receptor modulator (SERM) Soltamox®. Manufactured in WHO-GMP certified facilities, Tamoxican is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Tamoxifen Citrate works by competitively binding to estrogen receptors in breast tissue, thereby inhibiting estrogen-mediated proliferation of hormone-sensitive tumor cells. This mechanism helps reduce the risk of tumor growth and recurrence in estrogen receptor-positive (ER+) breast cancers.

Tamoxican 20 mg Tablets are primarily indicated for the treatment and adjuvant therapy of estrogen receptor-positive breast cancer in pre- and postmenopausal women, as well as for the prevention of breast cancer in high-risk patients.

Tamoxican 20 mg Tablets are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

Elevat Fluoxetine 20mg
Composition: Fluoxetine 20mg Capsules/Tablets
International Trade Name: Prozac®

Elevat 20mg is a high-quality Fluoxetine formulation, a selective serotonin reuptake inhibitor (SSRI) widely recognized under the international brand name Prozac®. Manufactured in WHO-GMP certified facilities, Elevat is supplied by trusted pharmaceutical exporters from India to support advanced mental health treatment programs worldwide.

Fluoxetine works by selectively inhibiting the reuptake of serotonin in the brain, helping to restore the balance of this neurotransmitter and improve mood, emotional state, and overall mental well-being. Elevat 20mg is primarily indicated for the treatment of major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, bulimia nervosa, and other psychiatric conditions where serotonergic modulation is beneficial.

Elevat Fluoxetine 20mg is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, mental health clinics, and international pharmaceutical distributors.

ProAlb Human Normal Albumin IP 20%
Composition: Human Normal Albumin 20% w/v Solution for Infusion
International Trade Name: Albutein® / Albuminar® 

ProAlb 20% is a high-quality Human Normal Albumin solution, a plasma-derived protein preparation widely used in critical care and volume replacement therapy. Manufactured in WHO-GMP certified facilities, ProAlb is supplied by trusted pharmaceutical exporters from India to support advanced global critical care, hepatology, and emergency medicine treatment programs.

Human Albumin is the most abundant plasma protein responsible for maintaining colloidal osmotic pressure, transporting endogenous and exogenous substances, and supporting intravascular volume expansion. ProAlb 20% Infusion is primarily indicated for the treatment of hypovolemia, shock, burns, hypoalbuminemia, liver cirrhosis, nephrotic syndrome, and during major surgical procedures where plasma volume support is required.

ProAlb Human Normal Albumin IP 20% is manufactured under stringent GMP and plasma safety standards, ensuring consistent efficacy, viral safety, and long-term stability. The solution is supplied in secure, sterile, export-grade packaging with complete regulatory documentation, making it suitable for intensive care units, hospitals, trauma centers, and international pharmaceutical distributors.

Innotubilin 120 Docetaxel Concentrate
Composition: Docetaxel 120 mg per vial
International Trade Name: Taxotere®

Innotubilin 120 is a high-quality Docetaxel concentrate, a biosimilar equivalent of the internationally recognized chemotherapeutic agent Taxotere®. Manufactured in WHO-GMP certified facilities, Innotubilin is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Docetaxel is a taxane-based chemotherapeutic agent that promotes microtubule stabilization, thereby inhibiting cell division and inducing apoptosis in rapidly proliferating cancer cells. Innotubilin is widely used in the treatment of various solid tumors, including breast, lung, prostate, gastric, and head and neck cancers.

Innotubilin 120 Docetaxel Concentrate is primarily indicated for the treatment of metastatic or locally advanced breast cancer, non-small cell lung cancer (NSCLC), hormone-refractory prostate cancer, and other solid tumors as determined by an oncologist, often as part of combination chemotherapy regimens.

Innotubilin 120 is manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, export-grade vials with complete regulatory documentation, making it suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

Bdbrut 140 mg Capsules
Composition: Ibrutinib 140 mg per capsule
International Trade Name: Imbruvica®

Bdbrut 140 mg is a high-quality Ibrutinib capsule, a biosimilar equivalent of the internationally recognized targeted therapy Imbruvica®. Manufactured in WHO-GMP certified facilities, Bdbrut is supplied by trusted pharmaceutical exporters from India to support advanced global oncology and hematology treatment programs.

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks critical signaling pathways required for the survival and proliferation of malignant B-cells. By inhibiting BTK, Bdbrut helps suppress tumor growth and induce apoptosis in cancerous cells, making it an effective targeted therapy for B-cell malignancies.

Bdbrut 140 mg Capsules are primarily indicated for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia, marginal zone lymphoma, and other selected B-cell malignancies, as prescribed by an oncologist.

Bdbrut 140 mg Capsules are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, specialty hospitals, government cancer programs, and international pharmaceutical distributors.

Erlolieva Erlotinib 150mg Tablets
Composition: Erlotinib 150mg Tablets
International Trade Name: Tarceva®

Erlolieva 150mg is a high-quality Erlotinib tablet formulation, a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor widely recognized under the international brand name Tarceva®. Manufactured in WHO-GMP certified facilities, Erlolieva is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in non-small cell lung cancer (NSCLC) and pancreatic cancer.

Erlotinib works by selectively inhibiting EGFR tyrosine kinase activity, blocking downstream signaling pathways responsible for cancer cell proliferation, survival, and angiogenesis. Erlolieva 150mg Tablets are primarily indicated for the treatment of locally advanced or metastatic NSCLC with EGFR mutations and for the treatment of locally advanced, unresectable, or metastatic pancreatic cancer in combination with gemcitabine.

Erlolieva Erlotinib 150mg Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Axilieva Axitinib 5mg Tablets
Composition: Axitinib 5mg Tablets
International Trade Name: Inlyta®

Axilieva 5mg is a high-quality Axitinib formulation, a potent and selective tyrosine kinase inhibitor (TKI) widely recognized under the international brand name Inlyta®. Manufactured in WHO-GMP certified facilities, Axilieva is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in renal cell carcinoma (RCC).

Axitinib works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), thereby blocking tumor angiogenesis and restricting the blood supply required for tumor growth and progression. Axilieva 5mg Tablets are primarily indicated for the treatment of advanced renal cell carcinoma, especially in patients who have received prior systemic therapy.

Axilieva Axitinib 5mg Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Aplazar Alpha Ketoanalogue Tablets
Composition: Alpha Ketoanalogue of Essential Amino Acids
International Trade Name: Ketosteril®

Aplazar is a high-quality Alpha Ketoanalogue tablet, a biosimilar equivalent of the internationally recognized renal nutrition therapy Ketosteril®. Manufactured in WHO-GMP certified facilities, Aplazar is supplied by trusted pharmaceutical exporters from India to support advanced global nephrology and renal care programs.

Alpha Ketoanalogues are nitrogen-free analogues of essential amino acids that help meet the body’s nutritional requirements without increasing nitrogen load. They are metabolized into essential amino acids in the body, thereby reducing the accumulation of uremic toxins and slowing the progression of chronic kidney disease (CKD) while maintaining adequate protein nutrition.

Aplazar Alpha Ketoanalogue Tablets are primarily indicated for the dietary management of chronic kidney disease (CKD), particularly in patients on low-protein diets. They help delay the need for dialysis, reduce metabolic complications, and improve overall nutritional status.

Aplazar Alpha Ketoanalogue Tablets are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for nephrology clinics, hospitals, government renal health programs, and international pharmaceutical distributors.

Docelieva 80 mg Injection
Composition: Docetaxel 80 mg per vial
International Trade Name: Taxotere®

Docelieva 80 mg Injection is a high-quality chemotherapeutic agent, a biosimilar equivalent of the internationally recognized anticancer drug Taxotere®. Manufactured in WHO-GMP certified facilities, Docelieva is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Docetaxel is a taxane-based chemotherapeutic agent that promotes microtubule stabilization, thereby inhibiting cell division and inducing apoptosis in rapidly proliferating cancer cells. Docelieva is widely used in the treatment of various solid tumors, including breast, lung, prostate, gastric, and head and neck cancers.

Docelieva 80 mg Injection is primarily indicated for the treatment of metastatic or locally advanced breast cancer, non-small cell lung cancer (NSCLC), hormone-refractory prostate cancer, and other solid tumors as determined by an oncologist, often as part of combination chemotherapy regimens.

Docelieva 80 mg Injection is manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, export-grade vials with complete regulatory documentation, making it suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

Afanat 40 mg Tablets
Composition: Afatinib 40 mg per tablet
International Trade Name: Gilotrif®

Afanat 40 mg is a high-quality Afatinib tablet, a biosimilar equivalent of the internationally recognized targeted therapy Gilotrif®. Manufactured in WHO-GMP certified facilities, Afanat is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in non-small cell lung cancer (NSCLC) with EGFR mutations.

Afatinib is an irreversible tyrosine kinase inhibitor (TKI) that selectively blocks signaling from the epidermal growth factor receptor (EGFR) family, including EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4). By inhibiting these pathways, Afanat helps prevent tumor cell proliferation, survival, and metastasis, making it an effective therapy for EGFR mutation-positive NSCLC.

Afanat 40 mg Tablets are primarily indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have non-resistant EGFR mutations, as prescribed by an oncologist.

Afanat 40 mg Tablets are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

Docekast Docetaxel Injection 80mg
Composition: Docetaxel 80mg / Vial Injection
International Trade Name: Taxotere®

Docekast 80mg is a high-quality Docetaxel injectable formulation, a semisynthetic taxane chemotherapeutic agent widely recognized under the international brand name Taxotere®. Manufactured in WHO-GMP certified facilities, Docekast Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Docetaxel works by promoting the assembly of microtubules and inhibiting their depolymerization, thereby disrupting the mitotic process and inducing apoptosis in rapidly dividing cancer cells. Docekast 80mg Injection is primarily indicated for the treatment of various malignancies, including breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancers, either as monotherapy or in combination with other chemotherapeutic agents.

Docekast Docetaxel Injection 80mg is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Cislieva 50 mg Injection
Composition: Cisplatin Injection IP 50 mg
International Trade Name: Platinol®

Cislieva 50 mg is a high-quality Cisplatin injection, a reliable generic equivalent of the internationally recognized platinum-based chemotherapeutic agent marketed under the brand name Platinol®. Manufactured in WHO-GMP certified facilities, Cislieva Injection is supplied by trusted pharmaceutical exporters from India to support global oncology treatment programs, particularly for solid tumors and other malignancies.

Cisplatin is a platinum-containing cytotoxic agent that works by forming DNA crosslinks, thereby interfering with DNA replication and transcription, leading to apoptosis in rapidly dividing cancer cells. Cislieva 50 mg Injection is primarily indicated for the treatment of testicular, ovarian, bladder, lung, cervical, and head & neck cancers, as well as other malignancies, either as monotherapy or in combination with other chemotherapeutic agents.

Cislieva Cisplatin Injection is manufactured under stringent GMP and sterile injectable quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Cislieva Cisplatin Injection 10mg
Composition: Cisplatin 10mg / Vial Injection
International Trade Name: Platinol®

Cislieva 10mg is a high-quality Cisplatin injectable formulation, a platinum-based chemotherapeutic agent widely recognized under the international brand name Platinol®. Manufactured in WHO-GMP certified facilities, Cislieva Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Cisplatin works by forming cross-links within DNA strands, thereby inhibiting DNA replication and transcription, leading to apoptosis in rapidly dividing cancer cells. Cislieva 10mg Injection is primarily indicated for the treatment of various malignancies, including testicular, ovarian, bladder, cervical, and lung cancers, either as monotherapy or in combination with other chemotherapeutic agents.

Cislieva Cisplatin Injection 10mg is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Docelieva 120 mg Injection
Composition: Docetaxel 120 mg per vial
International Trade Name: Taxotere®

Docelieva 120 mg Injection is a high-quality chemotherapeutic agent, a biosimilar equivalent of the internationally recognized anticancer drug Taxotere®. Manufactured in WHO-GMP certified facilities, Docelieva is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Docetaxel is a taxane-based chemotherapeutic agent that promotes microtubule stabilization, thereby inhibiting cell division and inducing apoptosis in rapidly proliferating cancer cells. Docelieva is widely used in the treatment of various solid tumors, including breast, lung, prostate, gastric, and head and neck cancers.

Docelieva 120 mg Injection is primarily indicated for the treatment of metastatic or locally advanced breast cancer, non-small cell lung cancer (NSCLC), hormone-refractory prostate cancer, and other solid tumors as determined by an oncologist, often as part of combination chemotherapy regimens.

Docelieva 120 mg Injection is manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, export-grade vials with complete regulatory documentation, making it suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

HYDROXYRA 500 Capsules
Composition: Hydroxyurea IP 500 mg per capsule
International Trade Name: Hydrea® / Litalir® / Droxia® / Siklos®

HYDROXYRA 500 is a high-quality Hydroxyurea capsule, a biosimilar equivalent of the internationally recognized antineoplastic and antimetabolite therapies Hydrea®, Litalir®, Droxia®, and Siklos®. Manufactured in WHO-GMP certified facilities, HYDROXYRA is supplied by trusted pharmaceutical exporters from India to support advanced global oncology and hematology treatment programs.

Hydroxyurea is an antimetabolite that works by inhibiting ribonucleotide reductase, an enzyme essential for DNA synthesis. By interfering with DNA replication, HYDROXYRA 500 helps slow or stop the growth of rapidly dividing cells, making it effective in the management of various malignancies and hematological disorders.

HYDROXYRA 500 Capsules are primarily indicated for the treatment of certain types of cancers, including chronic myelogenous leukemia (CML), head and neck cancers, and for the management of sickle cell disease to reduce the frequency of painful crises and the need for blood transfusions.

HYDROXYRA 500 Capsules are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, hematology clinics, government health programs, and international pharmaceutical distributors.

Udikast 300 mg Tablets
Composition: Ursodeoxycholic Acid 300 mg
International Trade Name: Actigall®

Udikast 300 mg is a high-quality Ursodeoxycholic Acid (UDCA) tablet, a biosimilar equivalent of the internationally recognized product Actigall®. Manufactured in WHO-GMP certified facilities, Udikast is supplied by trusted pharmaceutical exporters from India to support global hepatology and gastroenterology treatment programs.

Ursodeoxycholic Acid is a hydrophilic bile acid that reduces cholesterol absorption and promotes bile flow. It works by decreasing the cholesterol content of bile and stabilizing hepatocyte membranes, thereby protecting liver cells and aiding in the dissolution of cholesterol gallstones.

Udikast 300 mg Tablets are primarily indicated for the treatment of cholesterol gallstones in patients for whom surgery is not appropriate, management of primary biliary cholangitis (PBC), and improvement of liver function in cholestatic liver diseases.

Udikast 300 mg Tablets are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, gastroenterology clinics, government health programs, and international pharmaceutical distributors.

MELPHYRA 2mg Melphalan Tablets
Composition: Melphalan 2mg Tablets
International Trade Name: Alkeran®

MELPHYRA 2mg is a high-quality Melphalan tablet formulation, an alkylating chemotherapeutic agent widely recognized under the international brand name Alkeran®. Manufactured in WHO-GMP certified facilities, MELPHYRA is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hematological malignancies.

Melphalan works by interfering with DNA and RNA synthesis through alkylation, leading to inhibition of cell replication and induction of apoptosis in rapidly dividing cancer cells. MELPHYRA 2mg Tablets are primarily indicated for the treatment of multiple myeloma, ovarian cancer, and other selected malignancies, as well as in conditioning regimens prior to stem cell transplantation.

MELPHYRA 2mg Melphalan Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Mesalzer Mesalamine 1.2g
Composition: Mesalamine 1.2g Extended-Release Tablets
International Trade Name: Asacol®

Mesalzer 1.2g is a high-quality Mesalamine formulation, widely recognized under the international brand name Asacol®, used for the treatment of inflammatory bowel diseases. Manufactured in WHO-GMP certified facilities, Mesalzer is supplied by trusted pharmaceutical exporters from India to support advanced gastrointestinal treatment programs worldwide.

Mesalamine is an anti-inflammatory agent that acts locally on the colonic mucosa, inhibiting the production of pro-inflammatory mediators such as prostaglandins and leukotrienes, thereby reducing inflammation in the gastrointestinal tract. Mesalzer 1.2g is primarily indicated for the treatment and maintenance of remission in ulcerative colitis, including mild to moderate active disease.

Mesalzer Mesalamine 1.2g is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, gastroenterology clinics, and international pharmaceutical distributors.

Zubidox 10 Doxorubicin Hydrochloride Injection
Composition: Doxorubicin Hydrochloride 10 mg per pre-filled syringe (PFS)
International Trade Name: Adriamycin®

Zubidox 10 is a high-quality Doxorubicin Hydrochloride injection, a biosimilar equivalent of the internationally recognized anticancer drug Adriamycin®. Manufactured in WHO-GMP certified facilities, Zubidox 10 is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Doxorubicin Hydrochloride is an anthracycline chemotherapeutic agent that intercalates into DNA, inhibits topoisomerase II, and generates free radicals, leading to disruption of DNA replication and transcription, ultimately causing apoptosis in rapidly dividing cancer cells.

Zubidox 10 Injection is primarily indicated for the treatment of a wide range of malignancies, including breast cancer, ovarian cancer, lymphomas, leukemias, and soft tissue sarcomas, often as part of combination chemotherapy regimens.

Zubidox 10 Doxorubicin Hydrochloride Injection is manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The pre-filled syringe is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

Aprelieva Injection
Composition: Fosaprepitant Dimeglumine 150 mg per vial
International Trade Name: Emend®

Aprelieva is a high-quality Fosaprepitant Dimeglumine injection, a biosimilar equivalent of the internationally recognized antiemetic product Emend®. Manufactured in WHO-GMP certified facilities, Aprelieva is supplied by trusted pharmaceutical exporters from India to support advanced global oncology supportive care programs.

Fosaprepitant is a prodrug of aprepitant and acts as a selective neurokinin-1 (NK1) receptor antagonist. It prevents chemotherapy-induced nausea and vomiting (CINV) by blocking the action of substance P, a key mediator of vomiting in the central nervous system. Aprelieva is used in combination with other antiemetics for optimal control of acute and delayed CINV.

Aprelieva Injection is primarily indicated for the prevention of nausea and vomiting associated with highly emetogenic chemotherapy and for prevention of postoperative nausea and vomiting as prescribed by a healthcare professional.

Aprelieva Injection is manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology centers, hospitals, chemotherapy clinics, government health programs, and international pharmaceutical distributors.

Furmecil Tablets
Composition: Tegafur, Gimeracil, and Oteracil Combination
International Trade Name: Teysuno®

Furmecil is a high-quality oral anticancer formulation combining Tegafur, Gimeracil, and Oteracil, widely recognized under the international brand name Teysuno®. Manufactured in WHO-GMP certified facilities, Furmecil is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

This combination therapy works synergistically to enhance the efficacy of fluoropyrimidine-based chemotherapy. Tegafur is a prodrug of 5-fluorouracil (5-FU), Gimeracil inhibits the degradation of 5-FU to maintain its therapeutic plasma levels, and Oteracil reduces gastrointestinal toxicity by limiting 5-FU activity in the gut. Furmecil Tablets are primarily indicated for the treatment of advanced or recurrent gastric cancer, colorectal cancer, and other solid tumors where fluoropyrimidine therapy is indicated.

Furmecil Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Myfocept-S 360 Tablets
Composition: Mycophenolate Sodium 360 mg
International Trade Name: CellCept®

Myfocept-S 360 is a high-quality Mycophenolate Sodium tablet, a biosimilar equivalent of the internationally recognized immunosuppressant CellCept®. Manufactured in WHO-GMP certified facilities, Myfocept-S 360 is supplied by trusted pharmaceutical exporters from India to support advanced global transplant and immunosuppressive therapy programs.

Mycophenolate Sodium is an immunosuppressive agent that selectively inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo synthesis of guanosine nucleotides. By inhibiting lymphocyte proliferation, Myfocept-S 360 reduces the risk of organ rejection following kidney, heart, or liver transplantation.

Myfocept-S 360 Tablets are primarily indicated for the prevention of organ rejection in adult and pediatric patients receiving allogeneic kidney, heart, or liver transplants, as part of a combination immunosuppressive regimen.

Myfocept-S 360 is manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, transplant centers, government health programs, and international pharmaceutical distributors.

Rucaza 300 mg Tablets
Composition: Rucaparib 300 mg per tablet
International Trade Name: Rubraca®

Rucaza 300 mg is a high-quality Rucaparib tablet, a biosimilar equivalent of the internationally recognized PARP inhibitor Rubraca®. Manufactured in WHO-GMP certified facilities, Rucaza is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in targeted cancer therapy.

Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that interferes with DNA repair mechanisms in cancer cells. By blocking PARP enzymes, Rucaza promotes the accumulation of DNA damage in tumor cells, leading to cell death, especially in cancers with defective homologous recombination repair such as BRCA-mutated tumors.

Rucaza 300 mg Tablets are primarily indicated for the treatment and maintenance therapy of certain types of ovarian, fallopian tube, and primary peritoneal cancers, as prescribed by an oncologist. It is often used in patients with BRCA mutations or homologous recombination deficiency (HRD).

Rucaza 300 mg Tablets are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

Carfilnat Carfilzomib for Injection 60mg Vial
Composition: Carfilzomib 60mg for Injection
International Trade Name: Kyprolis®

Carfilnat 60mg is a high-quality Carfilzomib injectable formulation, a selective proteasome inhibitor widely recognized under the international brand name Kyprolis®. Manufactured in WHO-GMP certified facilities, Carfilnat Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multiple myeloma.

Carfilzomib works by selectively and irreversibly inhibiting the chymotrypsin-like activity of the 20S proteasome, leading to disruption of protein homeostasis in cancer cells, induction of apoptosis, and inhibition of tumor growth. Carfilnat 60mg Injection is primarily indicated for the treatment of relapsed or refractory multiple myeloma, either as monotherapy or in combination with other anticancer agents.

Carfilnat Carfilzomib for Injection 60mg Vial is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Cycokast-50 Cisplatin Injection 50mg
Composition: Cisplatin 50mg / mL Injection
International Trade Name: Platinol®

Cycokast-50 is a high-quality Cisplatin 50mg Injection, a platinum-based chemotherapeutic agent widely recognized under the international brand name Platinol®. Manufactured in WHO-GMP certified facilities, Cycokast-50 Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Cisplatin exerts its anticancer effect by forming cross-links in DNA, thereby interfering with DNA replication and transcription, leading to apoptosis of rapidly dividing cancer cells. Cycokast-50 Injection is primarily indicated for the treatment of various malignancies, including testicular, ovarian, bladder, cervical, lung cancers, and other solid tumors.

Cycokast-50 Cisplatin Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.